| Literature DB >> 30684400 |
José Côté1,2,3, Marie-Chantal Fortin3,4, Patricia Auger1,3, Geneviève Rouleau1,3, Sylvie Dubois2, Nathalie Boudreau4, Isabelle Vaillant4, Élisabeth Gélinas-Lemay4.
Abstract
BACKGROUND: Optimal immunosuppressive medication adherence is essential to graft survival. Transplant-TAVIE is a Web-based tailored intervention developed to promote this adherence.Entities:
Keywords: Web-based tailored intervention; medication adherence; nursing; randomized controlled trial; self-management; transplant recipient
Year: 2018 PMID: 30684400 PMCID: PMC6334708 DOI: 10.2196/formative.9707
Source DB: PubMed Journal: JMIR Form Res ISSN: 2561-326X
Figure 1Screenshot of Transplant-TAVIE intervention.
Figure 2Participant flow diagram. ANOVA: analysis of variance.
Baseline sociodemographics and clinical characteristics.
| Variable | Websites (control group, n=35) | ||||
| Male | 24 (69) | 22 (63) | |||
| Female | 11(31) | 13 (37) | |||
| Age (years), mean (SD) | 54.03 (9.75) | 51.37 (11.99) | |||
| Canadian | 29 (83) | 27 (77) | |||
| Other | 6 (17) | 8 (23) | |||
| ≤High school | 7 (22) | 9 (28) | |||
| >High school | 25 (78) | 23 (72) | |||
| Employed | 18 (51) | 19 (54) | |||
| Retired | 11 (31) | 6 (17) | |||
| Unemployed | 6 (17) | 10 (29) | |||
| <Can $15,000 | 1 (3) | 5 (14) | |||
| Can $15,001-Can $30,000 | 3 (9) | 6 (17) | |||
| Can $30,001-Can $50,000 | 9 (26) | 9 (26) | |||
| Can $50,0001-Can $100,000 | 11 (31) | 7 (20.0) | |||
| Other | 9 (26) | 8 (23) | |||
| Alone | 5 (14) | 6 (17) | |||
| With partner | 18 (51) | 22 (63) | |||
| With family, friend, roommate | 10 (29) | 5 (14) | |||
| Other | 1 (3) | 2 (6) | |||
| Single | 4 (12) | 7 (21) | |||
| Married or living common law | 28 (82) | 25 (74) | |||
| Divorced or widowed | 2 (6) | 2 (66) | |||
| Yes | 22 (65) | 15 (43) | |||
| No | 12 (35) | 20 (57) | |||
| Yes | 30 (88) | 30 (86) | |||
| No | 4 (12) | 5 (14) | |||
| Years since transplantation, mean (SD) | 7.6 (7.3) | 6.1 (5.4) | |||
| Wait time before transplantation (in months), mean (SD) | 35 (23) | 36 (28) | |||
| Living | 8 (23) | 15 (43) | |||
| Deceased | 26 (74) | 20 (57) | |||
Change in the adherence and secondary outcomes by the groups and over time (analysis of variance).
| Variable | Websites (control group), mean (SD) | Group × | ||||||
| Baseline | 3-month | 6-month | Baseline (n=35) | 3-month | 6-month | |||
| Adherence scorea | 11.4 (1.0) | 11.5 (0.8) | 11.7 (0.6) | 11.6 (0.7) | 11.7 (0.7) | 11.3 (2.0) | 1.65 (.20) | |
| Adherence visual scaleb | 97.1 (4.7) | 96.8 (6.4) | 98.7 (2.6) | 98.3 (3.9) | 98.7 (2.9) | 98.9 (2.0) | 0.45 (.64) | |
| Self-efficacyc | 1380.7 (60.7) | 1397.7 (17.0) | 1381.5 (37.9) | 1391.4 (21.0) | 1390.8 (17.1) | 1393.8 (14.4) | 1.02 (.37) | |
| Skillsd | 81.3 (14.8) | 79.8 (13.5) | 78.6 (14.3) | 79.0 (11.7) | 75.3 (15.3) | 77.4 (12.2) | 0.94 (.39) | |
| Degree bothered by side effectse,f | 1.1 (1.4) | 0.7 (1.0) | 0.9 (1.2) | 0.9 (1.3) | 1.3 (1.2) | 1.4 (1.2) | 0.85 (.44) | |
| Self-perceived state of healthg | 8.3 (1.1) | 8.2 (1.2) | 8.2 (1.4) | 8.1 (2.0) | 8.3 (1.7) | 7.9 (2.2) | 0.98 (.38) | |
aPossible score range: 0-12.
bPossible score range: 0-100.
cPossible score range: 0-1400.
dPossible score range: 0-96.
ePossible score range: 0-3.
fAmong those who presented medication side effects.
gPossible score range: 0-10.